Celularity Inc. is the next evolution in off-the-shelf allogeneic cellular therapies, at greater scale & quality with attractive economics. Led by an experienced management team with deep expertise in cell therapy, we are on a mission to harness the placenta’s unique biology and ready availability to develop therapeutic solutions.

Lead the evolution in placental-derived therapeutics: advance the discovery of the placenta as a renewable source of neonatal cells, which are biologically preferred to cells from adult bone marrow or peripheral blood

Target large markets with high unmet need: broad therapeutic application including cancer, degenerative, and infectious diseases

Develop safe and effective therapies: leverage inherent advantages of placental-derived cells to produce uniform, scalable and optimized cellular therapies

Deliver off-the-shelf, cost effective therapies: cryopreserved allogeneic cellular therapies that clinicians can access on demand and off-the-shelf, enabling repeat dosing/multiple cycles as required in an outpatient setting